Kura Oncology to Report Second Quarter 2020 Financial Results
July 30 2020 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for the treatment of cancer, today announced that it will
report second quarter 2020 financial results after the close of
U.S. financial markets on Thursday, August 6, 2020. Kura’s
management will host a webcast and conference call at 4:30 p.m. ET
/ 1:30 p.m. PT that day to discuss the financial results and
provide a corporate update.
The live call may be accessed by dialing (866) 278-7953 for
domestic callers and (323) 347-3281 for international callers and
entering the conference code: 1697775. A live webcast and archive
of the call will be available online from the investor relations
section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of two wholly
owned small molecule drug candidates that target cancer signaling
pathways where there is a strong scientific and clinical rationale
to improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s most advanced drug candidate is
tipifarnib, a potent, selective and orally bioavailable farnesyl
transferase inhibitor currently in a registration-directed trial
(AIM-HN) in patients with recurrent or metastatic HRAS mutant head
and neck squamous cell carcinoma. The Company’s pipeline is also
highlighted by KO-539, a potent and selective inhibitor of the
menin-KMT2A(MLL) protein-protein interaction currently in a Phase
1/2A clinical trial (KOMET-001) in patients with
relapsed/refractory acute myeloid leukemia. For additional
information about Kura, please visit the Company’s website at
www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024